Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from in...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Gastroenterology Council for Gut and Liver 2025-05-01
Σειρά:	Gut and Liver
Θέματα:	infliximab; pharmacokinetic model; intravenous; subcutaneous; inflammatory bowel diseases
Διαθέσιμο Online:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl240503
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!